June 15, 2012 | Scion Acquires Soft Tissue Biopsy Product Line

June 15, 2012 – Newton, Massachusetts.  Scion Medical Technologies, LLC (Scion), a company that manufactures and sells products in the general surgery area, announced today that it has acquired a suite of assets for soft tissue biopsy, including issued intellectual property for a novel approach in the field.  Scion is completing the final stages of development of the product and plans to submit a 510(k) toward the end of the calendar year.  This product line will augment the company’s product portfolio in biopsy, which already includes the Cassi II biopsy system, which Scion acquired in Q4 of 2012 and recently relaunched under the Scion label at the American Society of Breast Surgeons Annual Meeting in Phoenix, Arizona.

“The addition of our latest product line in soft tissue biopsy broadens our portfolio by providing our core customer base with an additional tool to detect and diagnose cancer.  Our Cassi II system has a long track record as an important tool in the detection of breast cancer.  This new product line will enable Scion to augment its product portfolio in breast cancer detection and expand into other soft tissue and organs,” said Scion’s CEO Joseph Siletto.  “With this transaction, Scion has completed two transactions in the past eight months and we continue to focus on additional acquisition opportunities in the medical device field.”

About Scion Medical Technologies
Scion Medical Technologies (Scion) is a global medical device company with US headquarters in Massachusetts. Scion has manufacturing, distribution and regulatory expertise in the US and China, and is actively looking to grow its product portfolio by acquiring and licensing medical devices that have received 510(k) clearance or premarket approval from the FDA, or are CE-Marked.